Claims for Patent: 7,612,164

Summary for Patent: 7,612,164

Title:	Cardiac muscle function and manipulation
Abstract:	This invention relates to polypeptides which affect myocardial cell differentiation and organisation of cardiac muscle contractile units, assay for identifying such polypeptides, and methods for improving cardiac function by the administration of such polypeptides to patients with heart disease. In one aspect, the invention provides a therapeutic composition comprising a peptide consisting of a fragment of human neuregulin .beta.2 isoform containing the EGF-like domain, e.g., SEQ ID NO.:2, and a physiologically acceptable carrier, excipient or stabilizer.
Inventor(s):	Zhou; Mingdong (La Jolla, CA)
Assignee:	Zensun (Shanghai) Science and Technologies Ltd. (Shanghai, CN)
Application Number:	11/429,027
Patent Claims:	1. A therapeutic composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a physiologically acceptable carrier, excipient or stabilizer. 2. The therapeutic composition of claim 1, which is an injectable therapeutic composition. 3. The therapeutic composition of claim 1, further comprising an agent that causes cardiac hypertrophy or congestive heart failure. 4. The therapeutic composition of claim 3, wherein the agent that causes cardiac hypertrophy or congestive heart failure is fludrocortisone acetate or herceptin. 5. The therapeutic composition of claim 1, further comprising an effective amount of an agent that acts to suppress a hypertrophy induction pathway different from the pathway suppressed by said peptide consisting of the amino acid of SEQ ID NO:2. 6. The therapeutic composition of claim 5, wherein the agent that acts to suppress a hypertrophy induction pathway different from the pathway suppressed by the peptide consisting of the amino acid sequence of SEQ ID NO:2 is selected from the group consisting of a cardiotrophic inhibitor, an angiotensin-converting enzyme (ACE) inhibitor, a human growth hormone, an IGF-I, an anti-hypertrophic, myocardiotrophic factor, an anti-arrhythmic factor and an inotropic factor. 7. The therapeutic composition of claim 1, further comprising an effective amount of an ACE inhibitor. 8. The therapeutic composition of claim 7, wherein the ACE inhibitor is selected from the group consisting of quinapril, ramipril, captopril, benazepril, fosinopril, lisinopril, enalapril and lisinopril. 9. The therapeutic composition of claim 1, further comprising an effective amount of an agent for treating hypertension. 10. The therapeutic composition of claim 9, wherein the agent for treating hypertension is selected from the group consisting of an antibody to the endothelia receptor, a .beta.-adrenoreceptor antagonist, an .alpha..sub.1-nonreceptor antagonist, an anti-oxidant, a .beta.-blocker and a growth hormone. 11. A therapeutic composition comprising an expression vector encoding a peptide consisting of the amino acid sequece of SEQ ID NO:2. 12. The therapeutic composition of claim 11, wherein the expression vector encoding a peptide consisting of the amino acid sequence of SEQ ID NO:2 is an Adenovirus or an Adeno-Associated Virus.

Details for Patent 7,612,164

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2018-12-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2018-12-21